We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Neuralstem Obtains UCSD Stem Cell Delivery System for use in Spinal Cord Trials
News

Neuralstem Obtains UCSD Stem Cell Delivery System for use in Spinal Cord Trials

Neuralstem Obtains UCSD Stem Cell Delivery System for use in Spinal Cord Trials
News

Neuralstem Obtains UCSD Stem Cell Delivery System for use in Spinal Cord Trials

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Neuralstem Obtains UCSD Stem Cell Delivery System for use in Spinal Cord Trials"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stem cell company, Neuralstem, Inc. has announced that it has exclusively licensed the "Spinal Multisegmental Cell and Drug Delivery System," invented by Dr. Martin Marsala at the University of California, San Diego (UCSD).

The exclusive, worldwide license to Neuralstem covers all fields of use and includes the right to grant sublicenses. Under the terms of the agreement, UCSD will be eligible for milestone payments and royalties and Neuralstem will assume the cost of development, manufacture and approval of the product.

"Neuralstem is actively pursuing human clinical trials for its human spinal cord stem cells to treat Ischemic Paraplegia, ALS and Traumatic Spinal Cord Injury," said Neuralstem CEO Richard Garr.

"All three indications require delivering our cells directly into the spinal cord. We believe that Dr. Marsala's injection device will allow for a minimally invasive injection of the cells into the spinal cord, thus significantly reducing the risk of the surgery to any patients receiving cell or drug therapy administered directly into the spinal cord."

The device provides a unique method for delivering cells horizontally along the length of the spinal cord," said Dr. Marsala, "which will reduce the number of entry sites needed for therapeutic intervention. We believe that this will greatly enhance the likelihood of success for treating many indications."

Dr. Marsala went on to say, "Neuralstem has not only shown a strong commitment to moving their spinal cord stem cells into the clinic, but to creating a therapy that can be broadly and safely delivered. We are excited to have them as our exclusive licensee for this important technology."

Advertisement